Table 1.
Demographics, clinical laboratory and histological features of subjects within the study.
| Case A (SS/SLE) | Case B (pSS) | |
|---|---|---|
| AGE (YR) | 33 | 54 |
| SEX | F | F |
| RACE | African American | Caucasian/Hispanic |
| DIAGNOSIS | SLE, Secondary SS1 | Primary SS, Secondary Raynaud’s Syndrome8 |
| OBJECTIVE FEATURES | ||
| LG2 | Positive | Positive |
| Schirmers3 | Negative | Negative |
| Biopsy Focal Score4 | 5 | 2.8 |
| Biopsy Pathology Interpretation | Focal lymphocytic sialadenitis | Focal lymphocytic sialadenitis |
| Whole Unstimulated Salivary Flow5 | Negative | Positive |
| Serum Antibody Status6 | Ro52, Ro60, La, RNP, Sm, RF | Ro52, Ro60, PL12, RF |
| SLE Criteria7 | Leukopenia, Lymphopenia Anti-Sm, Pos ANA, Malar Rash, Oral ulcers, Pleuritis, Persistant proteinuria |
N/A |
| Medications | Hydroxychloroquine, Methotrexate, Pregabalin, Ergocalciferol | Hydroxychloroquine |
1
Sjögren’s syndrome (SS);
2
Positive ≥ 4 (AECG Criteria);
3
Positive ≤ 5mm/5 min;
4
Positive ≥ 1 per 4mm2;
5
Positive ≤ 1.5mL/15 min;
6
Antibodies evaluated: Centromere B (CenB), Histone, Jo-1, La, Rhematoid Factor (RF), Ribosomal P (Rib P); Ribonuclear Protein 70K, A and C (RNP70K, A, C), Ro52, Ro60, Smith B (SmB);
7
Tan et al, Arthritis Rheum 1982;25:1271;
8
Self-Reported.